1. Scrip
  2. >>Therapy Areas

Amgen's Oncology Strategy: Building A Pipeline Of Novel Paradigm-Changing Drugs

 
• By Mandy Jackson

Amgen oncology development VP Greg Friberg talked to Scrip about the company's rapidly growing oncology portfolio. "This is our renaissance," he said.

T-cells attacking cancer_1200x675
Amgen's BiTE molecules recruit T-cells to targeted tumors. • Source: Shutterstock

Amgen Inc. is starting to reach key value-inflection points in its early-stage cancer drug pipeline as it attempts to develop a portfolio of innovative, differentiated therapies that will be effective on their own and build on the promise of immuno-oncology agents, such as PD-1 inhibitors.

The company has a well-established portfolio of blockbuster supportive care therapies, including the anemia treatment Epogen (epoetin alfa), neutropenia therapies Neupogen (filgrastim) and Neulasta (pegfilgrastim), and Xgeva

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.